Restenosis after percutaneous transluminal angioplasty: II. Possibilities for pharmacologic intervention
Review published in VASA (1996)
Abstract
Reocclusion after percutaneous transluminal angioplasty is a major mechanism contributing to morbidity of patients after catheterization. Until now, pharmacological approaches to the prevention of restenosis were mostly disappointing, as only the early phase of thrombotic reocclusion, in which platelet activation is a major patho-physiological mechanism, could be treated with inhibitors of platelet aggregation and coagulation. Recently, several new approaches to the pharmacotherapy of restenosis have been introduced, for example thromboxane receptor antagonists or synthase inhibitors, GPIIb/IIa antagonists and hirudin as new inhibitors of platelet aggregation and coagulation, PDGF antagonists as inhibitors of intimal proliferation, and modulators of endothelial cell function, some of which may be effective in the late phase of myointimal proliferation. However, many substances that had been promising in experimental restenosis have proven ineffective in the first clinical trials. More recently, molecular biological techniques are increasingly used in experimental angioplasty. The role of these different approaches for the prevention of restenosis still has to be proven in clinical trials.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Reocclusion after percutaneous transluminal angioplasty is a major mechanism contributing to morbidity of patients after catheterization.
Warum dies für die Hirudotherapie relevant ist
This review explores pharmacological approaches to preventing restenosis after percutaneous transluminal angioplasty, discussing both early-phase platelet aggregation and coagulation inhibitors and late-phase antiproliferative agents. The abstract identifies hirudin as one of several new inhibitors of platelet aggregation and coagulation introduced for the early phase of thrombotic reocclusion, while noting that many promising substances have proven ineffective in initial clinical trials. The abstract does not reference leeches, leech saliva, or hirudotherapy. Hirudin appears only as one agent in a broad pharmacological survey with no specific clinical data provided and no established connection to live leech therapy or ASH's domain.
Zitation
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026